Genesystem Co. Ltd. (363250) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Genesystem Co. Ltd. KRW 638, price KRW 4,170, upside -84.7%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genesystem Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range 2,995 KRW – 31,900 KRW · fair‑value band 476.47 KRW – 952.94 KRW · the 4,170 KRW price screens above the 638.47 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Genesystem Co. in your weekly email
Every Wednesday you see whether Genesystem Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents.
Show more
Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits. The company was incorporated in 2010 and is based in Daejeon, South Korea.
Stock analysis
Genesystem Co. Ltd. (363250) currently trades at 4,170 KRW, while our model-based Fair Value estimate is 638.47 KRW, 84.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: 476.47 KRW (bear) to 952.94 KRW (bull), the price of 4,170 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Genesystem Co. Ltd. reported revenue of 381M KRW in FY2025 versus 13.2B KRW in FY2021, a compound −58.8%/yr. Reported net income was −12.0B KRW in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 39% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −85%, 363250 screens richer than that median.
Fair Value models
Bear 476.47 KRWFair Value 638.47 KRWBull 952.94 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−68.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−52.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−50.8%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.1% (2020) → −2,540.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside−84.7% · Bottom 25%
Profitability
Return on assets−26.7% · Bottom 25%
Growth and dividend
Revenue growth419.0% · Top 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/S (TTM)0.03× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 28
PAST (return on equity)0· sector 11
HEALTH (low debt)88· sector 93
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genesystem Co. Ltd. (363250) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 638.47 KRW versus a price of 4,170 KRW, about −85% upside (overvalued).
What is the fair value of 363250?
Our model-based fair value for Genesystem Co. Ltd. is 638.47 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 4,170 KRW.
What is the quality score of 363250?
Genesystem Co. Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genesystem Co. Ltd. (363250)?
Our model-based price target is the fair value of 638.47 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 476.47 KRW, optimistic scenario 952.94 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genesystem Co. Ltd. stock forecast for 2026?
Our models put fair value at 638.47 KRW, about −85% upside versus a price of 4,170 KRW (overvalued). Cautious scenario 476.47 KRW, optimistic scenario 952.94 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genesystem Co. Ltd. (363250)?
Genesystem Co. Ltd. reported trailing-twelve-month revenue of about 647M KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Genesystem Co. Ltd. (363250)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genesystem Co. Ltd. it is 638.47 KRW per share (as of Oct 2, 2026), against a price of 4,170 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Genesystem Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 363250 trades above its calculated fair value: price 4,170 KRW, fair value 638.47 KRW, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 363250?
No. The price is what the market pays today (4,170 KRW); the fair value is what the company's own numbers justify (638.47 KRW). For Genesystem Co. Ltd. the two are 3,532 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genesystem Co. Ltd. worth?
The market values Genesystem Co. Ltd. at about 28.4B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 4,170 KRW; our models calculate a fair value of 638.47 KRW per share.
What do the bullish and bearish scenarios say about 363250?
Our models span a range for Genesystem Co. Ltd.: cautious scenario 476.47 KRW, base 638.47 KRW, optimistic 952.94 KRW per share (as of Oct 2, 2026, price 4,170 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genesystem Co. Ltd. (363250)?
Balance-sheet figures for Genesystem Co. Ltd. (as of Oct 2, 2026): return on equity −97.4%, debt of 0.25 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 363250 from its 52-week high?
Genesystem Co. Ltd. trades at 4,170 KRW, about 40% below its 52-week high of 6,990 KRW and 39% above the low of 2,995 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 638.47 KRW is for.
Which stocks are comparable to Genesystem Co. Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genesystem Co. Ltd. stock attractive at the current price?
The data as of Oct 2, 2026: price 4,170 KRW, calculated fair value 638.47 KRW (−85%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 363250 calculated?
We run Genesystem Co. Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 638.47 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Genesystem Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genesystem Co. Ltd. (363250)?
The closing price on Oct 2, 2026 was 4,170 KRW. Our model-based fair value is 638.47 KRW, about −85% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genesystem Co. Ltd. right now?
The price sits above even our optimistic bull case (952.94 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (476.47 KRW to 952.94 KRW) leaves room in how you read the outcome.
Key figures of Genesystem Co. Ltd.
How large is the market capitalisation of Genesystem Co. Ltd. (363250)?
The market capitalisation of Genesystem Co. Ltd. is 28.4B KRW (≈ $21.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genesystem Co. Ltd. (363250)?
The price-to-sales ratio of Genesystem Co. Ltd. is 41.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Genesystem Co. Ltd. (363250)?
The return on equity (ROE) of Genesystem Co. Ltd. is −97.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genesystem Co. Ltd. (363250)?
On an EBIT basis the return on assets of Genesystem Co. Ltd. is −27.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genesystem Co. Ltd. (363250)?
The operating margin of Genesystem Co. Ltd. is −490% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genesystem Co. Ltd. (363250)?
Revenue at Genesystem Co. Ltd. is growing +419% versus a year earlier (3y avg −52.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genesystem Co. Ltd. (363250) generate?
The free cash flow of Genesystem Co. Ltd. is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genesystem Co. Ltd. (363250) carry?
The net debt of Genesystem Co. Ltd. is 2.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genesystem Co. Ltd. in the live analysis
One click puts Genesystem Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
